MX363119B - Composicion farmaceutica. - Google Patents
Composicion farmaceutica.Info
- Publication number
- MX363119B MX363119B MX2014013091A MX2014013091A MX363119B MX 363119 B MX363119 B MX 363119B MX 2014013091 A MX2014013091 A MX 2014013091A MX 2014013091 A MX2014013091 A MX 2014013091A MX 363119 B MX363119 B MX 363119B
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- subject
- compound
- combination
- administration
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 7
- 230000002608 insulinlike Effects 0.000 abstract 7
- 230000002641 glycemic effect Effects 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 3
- 108090001061 Insulin Proteins 0.000 abstract 3
- 230000009286 beneficial effect Effects 0.000 abstract 3
- 229940125396 insulin Drugs 0.000 abstract 3
- 235000012054 meals Nutrition 0.000 abstract 3
- 102000016261 Long-Acting Insulin Human genes 0.000 abstract 2
- 108010092217 Long-Acting Insulin Proteins 0.000 abstract 2
- 229940100066 Long-acting insulin Drugs 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166252 | 2012-05-01 | ||
| EP12166251 | 2012-05-01 | ||
| US201261641540P | 2012-05-02 | 2012-05-02 | |
| US201261641544P | 2012-05-02 | 2012-05-02 | |
| PCT/EP2013/059073 WO2013164375A1 (en) | 2012-05-01 | 2013-05-01 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013091A MX2014013091A (es) | 2014-12-08 |
| MX363119B true MX363119B (es) | 2019-03-11 |
Family
ID=49514218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013091A MX363119B (es) | 2012-05-01 | 2013-05-01 | Composicion farmaceutica. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9884094B2 (OSRAM) |
| EP (1) | EP2844274B1 (OSRAM) |
| JP (1) | JP6262206B2 (OSRAM) |
| AU (1) | AU2013255880B2 (OSRAM) |
| BR (1) | BR112014026442A8 (OSRAM) |
| CA (1) | CA2872083A1 (OSRAM) |
| MX (1) | MX363119B (OSRAM) |
| RU (1) | RU2670106C2 (OSRAM) |
| WO (1) | WO2013164375A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2505593A1 (en) | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
| JP6755175B2 (ja) * | 2013-03-20 | 2020-09-16 | ノヴォ ノルディスク アー／エス | インスリン投薬レジメン |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| WO2016001185A1 (en) * | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
| US20250154220A1 (en) * | 2023-11-15 | 2025-05-15 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| WO1990007522A1 (en) | 1988-12-23 | 1990-07-12 | Novo Nordisk A/S | Human insulin analogues |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| HUT64022A (en) | 1989-04-19 | 1993-11-29 | Enzon Inc | Process for producing active polyalkileneoxide carbonates for the modification of polypeptides |
| DE122004000035I2 (de) | 1993-09-17 | 2009-08-06 | Novo Nordisk As | Acyliertes insulin |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6531448B1 (en) * | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| PT2107069E (pt) | 2003-08-05 | 2013-04-23 | Novo Nordisk As | Novos derivados de insulina |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| EP2505593A1 (en) | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| MX2008014061A (es) | 2006-05-09 | 2008-11-14 | Novo Nordisk As | Derivado de insulina. |
| CN101677947B (zh) | 2007-06-13 | 2013-07-17 | 诺沃-诺迪斯克有限公司 | 包含胰岛素衍生物的药物制剂 |
| KR101556514B1 (ko) * | 2008-02-19 | 2015-10-02 | 바이오콘 리미티드 | 효모에서 발현된 정제된 이형 인슐린을 수득하는 방법 |
| AU2009309623B9 (en) * | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| EP2632478B1 (en) | 2010-10-27 | 2019-07-24 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections administered with varying injection intervals |
-
2013
- 2013-05-01 US US14/398,018 patent/US9884094B2/en active Active
- 2013-05-01 EP EP13721650.3A patent/EP2844274B1/en active Active
- 2013-05-01 AU AU2013255880A patent/AU2013255880B2/en active Active
- 2013-05-01 CA CA 2872083 patent/CA2872083A1/en not_active Withdrawn
- 2013-05-01 RU RU2014147674A patent/RU2670106C2/ru active
- 2013-05-01 JP JP2015509430A patent/JP6262206B2/ja active Active
- 2013-05-01 WO PCT/EP2013/059073 patent/WO2013164375A1/en not_active Ceased
- 2013-05-01 MX MX2014013091A patent/MX363119B/es unknown
- 2013-05-01 BR BR112014026442A patent/BR112014026442A8/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013255880B2 (en) | 2017-07-20 |
| EP2844274B1 (en) | 2019-03-20 |
| JP6262206B2 (ja) | 2018-01-17 |
| MX2014013091A (es) | 2014-12-08 |
| RU2670106C2 (ru) | 2018-10-18 |
| US20150126439A1 (en) | 2015-05-07 |
| RU2014147674A (ru) | 2016-06-27 |
| WO2013164375A1 (en) | 2013-11-07 |
| EP2844274A1 (en) | 2015-03-11 |
| AU2013255880A1 (en) | 2014-10-16 |
| CA2872083A1 (en) | 2013-11-07 |
| BR112014026442A2 (pt) | 2017-06-27 |
| BR112014026442A8 (pt) | 2018-01-16 |
| JP2015517458A (ja) | 2015-06-22 |
| US9884094B2 (en) | 2018-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX363119B (es) | Composicion farmaceutica. | |
| PH12019500517A1 (en) | Long-acting formulations of insulins | |
| PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| MX2022004041A (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos. | |
| MX375745B (es) | Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada. | |
| HRP20251088T1 (hr) | Upotreba dugodjelujućih peptida glp‑1 | |
| MY183793A (en) | Pharmaceutical compositions | |
| NZ714273A (en) | Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof | |
| UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
| WO2011087835A3 (en) | Novel compositions and methods for treating inflammatory bowel disease and airway inflammation | |
| NZ602380A (en) | Peptides for vaccine against birch allergy | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| AU2012207301A8 (en) | Apolipoprotein AIV as an antidiabetic peptide | |
| MX342417B (es) | Composicion antioxidante para reducir el estres oxidativo atribuible al tratamiento con farmacos anticonceptivos hormonales. | |
| WO2013084070A3 (en) | Salmonella vaccine proteins | |
| WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
| NZ707168A (en) | Pharmaceutical composition of insulins | |
| WO2011163321A3 (en) | Composition and method of treating lipid encapsulated virus infections | |
| WO2013090965A3 (de) | Zusammensetzung enthaltend antikörper gegen gluten und gerbstoffe | |
| PH12013500027A1 (en) | Therapeutic agents 976 | |
| ES2385683A1 (es) | Composiciones para el tratamiento del dolor y/o la inflamación. | |
| HK1229209A1 (en) | Method and products for enhancing cellular uptake of drug and dietary supplements | |
| IN2013MU01156A (OSRAM) | ||
| NZ720788A (en) | Eczema treatment |